Gabriela Rondon

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis
    Gabriela Rondon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:859-66. 2008
  2. pmc Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
  3. pmc Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:474-80. 2013
  4. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
  5. ncbi request reprint A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 19:1453-8. 2013
  6. pmc Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission
    Ulas D Bayraktar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 19:898-903. 2013
  7. pmc High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
  8. ncbi request reprint Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
  9. doi request reprint Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation
    Carlos A Ramos
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:686-94. 2010
  10. doi request reprint Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:923-9. 2011

Detail Information

Publications43

  1. ncbi request reprint Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis
    Gabriela Rondon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:859-66. 2008
    ..Collection of autologous stem cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals...
  2. pmc Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
    ..9, P = .008, HR for OS = 1.8, P = .07). Gem-Bu-Mel improved outcomes in this cohort analysis of patients with refractory/poor-risk relapsed HL and merits evaluation in randomized phase III trials...
  3. pmc Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:474-80. 2013
    ..017); and overall survival, 27% versus 9% (P = .02). We conclude that optimizing i.v. busulfan dose intensity in the preparative regimen may overcome disease-associated poor prognostic factors...
  4. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
    ..Further studies should be conducted in carefully designed clinical trials in this patient population...
  5. ncbi request reprint A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 19:1453-8. 2013
    ..6 versus 9.6 months in patients with <VGPR, P = .05). OS was similar across all variables. We conclude that FM100 and FM140 may result in similar patient outcomes after allo-HCT for MM...
  6. pmc Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission
    Ulas D Bayraktar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 19:898-903. 2013
    ..Survival and relapse-free survival are similar after TCD and conventional transplants from related/unrelated donors in patients with AML in CR1, but TCD significantly reduces GVHD...
  7. pmc High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    ..In conclusion, gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials...
  8. ncbi request reprint Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
    ..01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control...
  9. doi request reprint Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation
    Carlos A Ramos
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:686-94. 2010
    ..Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of transplantation does not seem to adversely affect outcome after allo-HSCT...
  10. doi request reprint Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:923-9. 2011
    ..A higher incidence of graft rejection was identified in the mismatched related donor group (P = .02). These results indicate that transplant outcomes are better with a MUD than with a 1 antigen/allele-mismatched related donor...
  11. pmc Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1841-5. 2011
    ....
  12. doi request reprint Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:1490-6. 2011
    ..Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS...
  13. ncbi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
    ..Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates...
  14. doi request reprint Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation
    Li Mei Poon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Biol Blood Marrow Transplant 19:1059-64. 2013
    ..8). Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared...
  15. pmc Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization
    Veronica R Smith
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:754-7. 2013
    ..93 × 10(6) /kg of body weight. The median CD34+ cell dose collected for patients with multiple myeloma was 8.81 × 10(6) /kg of body weight. Plerixafor was well tolerated; no grade 2 or higher non-hematologic toxic effects were observed...
  16. ncbi request reprint The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy
    Yee Chung Cheng
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:794-804. 2004
    ..In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting...
  17. ncbi request reprint Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 18:584-92. 2012
    ..Allogeneic HSCT provides durable remission for patients with Ph+ ALL in first remission. Neither TKI use pre- nor post-HSCT were found to significantly impact transplant outcomes in univariate and multivariate analyses...
  18. pmc Durable remission with salvage second autotransplants in patients with multiple myeloma
    Nina Shah
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3549-55. 2012
    ..However, the role of salvage auto-HCT for relapsed patients, particularly in the era of novel therapeutics, is not well defined...
  19. pmc Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:893-900. 2011
    ..Additional studies to evaluate the antileukemic efficacy of Clo ± Flu with i.v. Bu as pretransplant conditioning therapy are warranted...
  20. ncbi request reprint Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 18:1835-44. 2012
    ..These results indicate that a TCR graft followed by effective control of GVHD posttransplantation may lower NRM and improve survival after haploidentical SCT...
  21. pmc Cord-blood engraftment with ex vivo mesenchymal-cell coculture
    Marcos de Lima
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 367:2305-15. 2012
    ..We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells...
  22. pmc Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:5957-64. 2011
    ..1%; P < .0001) and higher in women with 1 (P = .008) and 2 or more pregnancies (P = .0003) than in men. We conclude that the presence of anti-DPB1 DSAs is associated with graft failure in MUD hematopoietic stem cell transplantation...
  23. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  24. ncbi request reprint Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  25. doi request reprint Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant
    Amer M Beitinjaneh
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Leuk Lymphoma 53:1525-9. 2012
    ..The role of DLI needs to be further explored in prospective clinical trials...
  26. doi request reprint Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1169-75. 2011
    ..These results suggest that ALC recovery is an important prognostic indicator for patients treated with cord blood and T cell-depleted peripheral haploidentical transplants...
  27. doi request reprint Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 117:3641-7. 2011
    ..Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI...
  28. doi request reprint Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2884-7. 2009
    ..05). We conclude that MICA may represent novel a transplantation antigen recognized by human allogeneic T cells. This study was registered at ClinicalTrials.gov (Identifier NCT00506922)...
  29. doi request reprint Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation
    Aimee E Hammerstrom
    Division of Pharmacy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Am J Hematol 88:301-5. 2013
    ..PRES was associated with high blood pressure and adequate blood pressure control should be part of its management. No management strategy pertaining to tacrolimus usage appeared more beneficial over another...
  30. doi request reprint Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections
    Dimpy P Shah
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Antimicrob Chemother 68:1872-80. 2013
    ....
  31. ncbi request reprint Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I
    Nikolai Velev
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3631-7. 2010
    ..The outcome in such patients after stem cell transplantation (SCT) is unknown...
  32. pmc Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
    Elias Jabbour
    Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 88:198-200. 2013
    ..001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era...
  33. doi request reprint Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation
    Jonas A de Souza
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 15:1094-9. 2009
    ..05). There were no differences in OS and NRM at day 100 and 1-year posttransplantation in the 3 groups by any GFR estimation method. In conclusion, a mild to moderate decrease in GFR was not associated with an increase in NRM...
  34. ncbi request reprint Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation
    Naveen Pemmaraju
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma Leuk 13:485-92. 2013
    ..Outcomes in patients with acute promyelocytic leukemia (APL) have improved; however, a significant number of patients still relapse despite receiving all-trans-retinoic acid (ATRA) and arsenic-based therapies...
  35. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
    Richard Champlin
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S261-5. 2009
    ..This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions...
  36. doi request reprint Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement
    Hassan Khan
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1551-5. 2011
    ..Temporary placement of a percutaneous nephrostomy catheter relieved the obstruction and significantly improved kidney function, successfully preventing progression to more advanced renal disease in these patients...
  37. pmc Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Carlos A Ramos
    Department of Stem Cell, Transplantation and Cellular Therapy, The University of Texas M D, Anderson Cancer Center 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Haematologica 94:249-57. 2009
    ....
  38. pmc Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies
    Partow Kebriaei
    Division of Cancer Medicine, M D Anderson Cancer Center, Houston, TX 77005, USA
    Hum Gene Ther 23:444-50. 2012
    ..The results of this study will lay the foundation for future protocols including CAR(+) T-cell infusions derived from allogeneic sources...
  39. ncbi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
    ..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT...
  40. ncbi request reprint Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time
    Kazutaka Nakayama
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:1465-74. 2009
    ..Such counseling is crucial for patients who are young and childless...
  41. ncbi request reprint Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells
    Martin Korbling
    Departments of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 346:738-46. 2002
    ..Bone marrow contains stem cells with the potential to differentiate into mature cells of various organs. We determined whether circulating stem cells have a similar potential...
  42. ncbi request reprint Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002
    ..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...
  43. ncbi request reprint Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:131-4. 2002
    ..This report provides proof of principle for the feasibility of non-myeloablative transplantation for patients with idiopathic HES, who can show co-morbidity due to eosinophilic infiltration of their organs...